))
Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.
…
continue reading
1
Anti-Obesity Drug Targets the CB1 Receptor via the Endocannabinoid System with Punit Dhillon Skye Bioscience TRANSCRIPT
Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid sy…
…
continue reading
1
Anti-Obesity Drug Targets the CB1 Receptor via the Endocannabinoid System with Punit Dhillon Skye Bioscience
16:58
16:58
Play later
Play later
Lists
Like
Liked
16:58
Punit Dhillon, Chairman and CEO of Skye Bioscience, focuses on anti-obesity and developing a drug that targets the cannabinoid receptor 1, which plays a role in signaling the body to store fat. The next generation of CB1 inhibition moves from a centrally mediated pathway to targeting CB1 receptors outside the brain. Deploying the endocannabinoid sy…
…
continue reading
1
Antibody Drug Conjugate Targets Claudin 18.2 to Treat Gastric Cancer with Joe Ferra Elevation Oncology TRANSCRIPT
Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.…
…
continue reading
1
Antibody Drug Conjugate Targets Claudin 18.2 to Treat Gastric Cancer with Joe Ferra Elevation Oncology
18:01
18:01
Play later
Play later
Lists
Like
Liked
18:01
Joe Ferra, CEO of Elevation Oncology, highlights the unmet needs in gastric cancer and the potential of targeting Claudins, proteins involved in cell adhesion. The current competitive landscape of antibody drug conjugates (ADCs) confirms the promise of a targeted therapy that delivers a cytotoxic drug directly to cancer cells. Targeting Claudin 18.…
…
continue reading
1
Role of AI and Pharmacists in Medication Therapy Optimization with Dr. Steve Goldberg DecisionRx and Jamie Wilkey TRANSCRIPT
Dr. Steve Goldberg, physician and Senior Clinical Advisor at DecisionRx, and Dr. Jamie Wilkey, pharmacist and expert on medication therapy optimization, explain that medications are the fourth leading cause of death in the country. They emphasize the need to consider genetic information and pharmacogenomics to design personalized medication plans t…
…
continue reading
1
Role of AI and Pharmacists in Medication Therapy Optimization with Dr. Steve Goldberg DecisionRx and Jamie Wilkey
16:23
16:23
Play later
Play later
Lists
Like
Liked
16:23
Dr. Steve Goldberg, physician and Senior Clinical Advisor at DecisionRx, and Dr. Jamie Wilkey, pharmacist and expert on medication therapy optimization, explain that medications are the fourth leading cause of death in the country. They emphasize the need to consider genetic information and pharmacogenomics to design personalized medication plans t…
…
continue reading
1
Taking the Guesswork Out of Medical Bills and Providing Patient Payment Options with Ryne Natzke TrustCommerce TRANSCRIPT
Ryne Natzke is the Chief Revenue Officer for TrustCommerce, a Sphere company that facilitates electronic payments in the healthcare industry, helping ensure security and compliance in transactions between patients and providers. Healthcare payments present unique challenges, as patients have varying preferences and are impacted by economic factors …
…
continue reading
1
Taking the Guesswork Out of Medical Bills and Providing Patient Payment Options with Ryne Natzke TrustCommerce
17:50
17:50
Play later
Play later
Lists
Like
Liked
17:50
Ryne Natzke is the Chief Revenue Officer for TrustCommerce, a Sphere company that facilitates electronic payments in the healthcare industry, helping ensure security and compliance in transactions between patients and providers. Healthcare payments present unique challenges, as patients have varying preferences and are impacted by economic factors …
…
continue reading
1
Medical Marketplace for Hospitals and Surgery Centers of Stale or Excess Inventory Saves Money Reduces Waste with Dr. Andrew Dold RevMed TRANSCRIPT
Dr. Andrew Dold, Co-Founder of RevMed, a B2B marketplace for hospitals and ambulatory surgery centers (ASCs) to address the problem of slow-moving or expiring inventory. This medical marketplace allows facilities to recoup lost revenue by listing medical devices for sale and offers purchasing options for smaller facilities. RevMed serves as a middl…
…
continue reading
1
Medical Marketplace for Hospitals and Surgery Centers of Stale or Excess Inventory Saves Money Reduces Waste with Dr. Andrew Dold RevMed
16:12
16:12
Play later
Play later
Lists
Like
Liked
16:12
Dr. Andrew Dold, Co-Founder of RevMed, a B2B marketplace for hospitals and ambulatory surgery centers (ASCs) to address the problem of slow-moving or expiring inventory. This medical marketplace allows facilities to recoup lost revenue by listing medical devices for sale and offers purchasing options for smaller facilities. RevMed serves as a middl…
…
continue reading
1
Unlocking Secrets of the Ocean for Marine-Based Research and Drug Discovery with Ed Esquenazi Sirenas TRANSCRIPT
Ed Esquenazi, Founder and CEO of Sirenas, is exploring the chemistry of marine organisms to accelerate drug discovery. Marine-based scientific elements are still poorly understood but have the potential to produce unique and useful compounds for drug development. There are stark differences between land-based organisms and marine-based organisms, w…
…
continue reading
1
Unlocking Secrets of the Ocean for Marine-Based Research and Drug Discovery with Ed Esquenazi Sirenas
16:36
16:36
Play later
Play later
Lists
Like
Liked
16:36
Ed Esquenazi, Founder and CEO of Sirenas, is exploring the chemistry of marine organisms to accelerate drug discovery. Marine-based scientific elements are still poorly understood but have the potential to produce unique and useful compounds for drug development. There are stark differences between land-based organisms and marine-based organisms, w…
…
continue reading
Kim Perry, Chief Growth Officer at emtelligent, focuses on using medical AI in the prior authorization process to structure unstructured medical text in patient records, making whole record healthcare possible. AI can be used to extract relevant information from faxed or PDF medical records, saving time and improving efficiency over existing manual…
…
continue reading
1
Using Medical AI to Accelerate the Prior Approval Process with Kim Perry emtelligent
19:44
19:44
Play later
Play later
Lists
Like
Liked
19:44
Kim Perry, Chief Growth Officer at emtelligent, focuses on using medical AI in the prior authorization process to structure unstructured medical text in patient records, making whole record healthcare possible. AI can be used to extract relevant information from faxed or PDF medical records, saving time and improving efficiency over existing manual…
…
continue reading
1
Developing Gene Therapy for Friedreich’s Ataxia Cardiomyopathy with Nolan Townsend Lexeo Therapeutics and Jen Farmer FARA TRANSCRIPT
Nolan Townsend, CEO of Lexeo Therapeutics, and Jen Farmer, CEO of FARA, the Friedreich's Ataxia Research Alliance, are working together to better understand and treat Friedreich's Ataxia. This rare genetic condition includes cardiomyopathy and scoliosis. Lexeo Therapeutics is studying gene therapy as a potential treatment for the cardiovascular com…
…
continue reading
1
Developing Gene Therapy for Friedreich’s Ataxia Cardiomyopathy with Nolan Townsend Lexeo Therapeutics and Jen Farmer FARA
18:20
18:20
Play later
Play later
Lists
Like
Liked
18:20
Nolan Townsend, CEO of Lexeo Therapeutics, and Jen Farmer, CEO of FARA, the Friedreich's Ataxia Research Alliance, are working together to better understand and treat Friedreich's Ataxia. This rare genetic condition includes cardiomyopathy and scoliosis. Lexeo Therapeutics is studying gene therapy as a potential treatment for the cardiovascular com…
…
continue reading
1
How Technology Can Streamline Physician Workflow and Improve Patient Care with Dr. Craig Joseph Nordic Global TRANSCRIPT
Dr. Craig Joseph, Chief Medical Officer at Nordic Global, highlights the concerns and challenges healthcare professionals face when using health IT and the clinician burnout related to the administrative burdens of electronic health records. He addresses the obstacles to integrating IT into healthcare workflows, including cost, risk aversion, and r…
…
continue reading
1
How Technology Can Streamline Physician Workflow and Improve Patient Care with Dr. Craig Joseph Nordic Global
23:01
23:01
Play later
Play later
Lists
Like
Liked
23:01
Dr. Craig Joseph, Chief Medical Officer at Nordic Global, highlights the concerns and challenges healthcare professionals face when using health IT and the clinician burnout related to the administrative burdens of electronic health records. He addresses the obstacles to integrating IT into healthcare workflows, including cost, risk aversion, and r…
…
continue reading
1
Promoting Natural Repair of Spinal Cord Injury and Restoration of Central Nervous System Connectivity with Mike Kelly NervGen Pharma TRANSCRIPT
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targe…
…
continue reading
1
Promoting Natural Repair of Spinal Cord Injury and Restoration of Central Nervous System Connectivity with Mike Kelly NervGen
16:56
16:56
Play later
Play later
Lists
Like
Liked
16:56
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targe…
…
continue reading
1
Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of Kaizen TRANSCRIPT
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importanc…
…
continue reading
1
Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of Kaizen
19:59
19:59
Play later
Play later
Lists
Like
Liked
19:59
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importanc…
…
continue reading
1
Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology TRANSCRIPT
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A r…
…
continue reading
1
Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology
18:16
18:16
Play later
Play later
Lists
Like
Liked
18:16
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A r…
…
continue reading
1
New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma TRANSCRIPT
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the …
…
continue reading
